About laurabbook@gmail.com

This author has not yet filled in any details.
So far laurabbook@gmail.com has created 113 blog entries.
21 January 2021

Genetic Heterogeneity of MET-aberrant Non-Small Cell Lung Cancer and its Impact on the Outcome of Immunotherapy

2021-01-21T14:11:00-08:00

*December 2020* Robust data on the outcome of MET-aberrant non-small cell lung cancer (NSCLC) with non-targeted therapies is limited, especially in

Genetic Heterogeneity of MET-aberrant Non-Small Cell Lung Cancer and its Impact on the Outcome of Immunotherapy2021-01-21T14:11:00-08:00
21 January 2021

Increased Attention on Testing for Oncogenic Drivers in NSCLC Advances the Promise of Precision Medicine

2021-01-21T13:51:07-08:00

*December 2020* Identification of key oncogenic drivers and the development of targeted therapies with clinical activity in patients harboring actionable

Increased Attention on Testing for Oncogenic Drivers in NSCLC Advances the Promise of Precision Medicine2021-01-21T13:51:07-08:00
21 January 2021

Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status

2021-01-21T13:43:12-08:00

*November 2020* Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, efficiently penetrates the blood-brain barrier. This study explored whether treatment with

Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status2021-01-21T13:43:12-08:00
21 January 2021

Manochakian Calls for Repeat Genomic Testing Upon Osimertinib Progression in EGFR+ NSCLC

2021-01-21T13:33:16-08:00

*December 2020* Because no standard approaches exist for patients with EGFR-mutated non–small cell lung cancer (NSCLC) who progress on standard frontline

Manochakian Calls for Repeat Genomic Testing Upon Osimertinib Progression in EGFR+ NSCLC2021-01-21T13:33:16-08:00
6 January 2021

New Clinical Trial: Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

2021-01-06T14:40:10-08:00

*November 2020* This new clinical trial is for those people whose EGFR lung cancer has transformed to small cell lung

New Clinical Trial: Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors2021-01-06T14:40:10-08:00
Go to Top